Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ion Channel-Expressing Cell Lines and Discovery Services

By Drug Discovery Trends Editor | August 27, 2008

ChanTest has an expanding line of ion channel services designed to give drug-discovery researchers the early information to identify the most promising compounds, and eliminate those that could be harmful. In addition, the company’s ion channel cell lines and services are used to help rescue shelved pharmaceutical compounds.

“Over the years the pharmaceutical and biotech industries have shelved thousands of promising drug candidates because they may induce cardiac or other dangerous side effects in a small subset of potential users,” said Dr. Arthur “Buzz” Brown. “This warehouse of extant, withdrawn, or discontinued drugs represents billions of dollars of discovery and development cost. Our safety assays and rapidly expanding library of ion channel-expressing cell lines are offering new hope to drug-discovery researchers looking to recover and repurpose some of those candidates and recoup their previous investment.

“For example, we identified a client’s compound that had failed for lack of efficacy but had an intriguing profile in one of our ion channel panel screens. After validation in an animal model of atrial fibrillation (AF), compound CT-1 is being tested for termination of AF in a Phase 2a proof-of-concept clinical trial. Initial results of oral administration in 22 patients show a termination rate of ~ 70 percent, well above the 30-percent rate for the antiarrhytmics used presently.”

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole). ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans.

Release Date: July 17, 2008
Source: ChanTest 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50